• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Self-rated health and venous thromboembolism among middle-aged women: a population-based cohort study
This study supports previous results with varico se veins and waist circumference as strong predictors of VTE. Poor self-rated health does not seem to be a valid predictor of VTE. Among lifestyle-related parameters, smoking was significantly associated with risk of VTE. We could also confirm the effect of the other already known risk factors.
Source: Journal of Thrombosis and Thrombolysis - November 18, 2019 Category: Hematology Source Type: research

Is there a role for low-dose DOACs as prophylaxis?
Authors: Cohen AT, Hunt BJ Abstract The direct oral anticoagulants (DOACs) have transformed the management of thrombotic disorders. Large clinical trials have demonstrated that DOACs can replace vitamin K antagonists (VKAs) in the 2 existing major indications for anticoagulation: the prevention of stroke in atrial fibrillation and the acute treatment and secondary prevention of venous thromboembolism (VTE); this literature is widely known. In this article, we will concentrate on the less well-discussed benefits of the use of DOACs-using low doses as primary and secondary prophylaxis in both venous and arterial thro...
Source: Hematology ASH Education Program - December 7, 2019 Category: Hematology Tags: Hematology Am Soc Hematol Educ Program Source Type: research

Drug interactions and pharmacogenetic factors contribute to variation in apixaban concentration in atrial fibrillation patients in routine care
In this study, we assessed the impact of interacting medication and pharmacogenetic variation to better explain apixaban concentration differences among 358 Caucasian AF patients. Genotyping (ABCG2,ABCB1,CYP3A4*22,CYP3A5*3) was performed by TaqMan assays, and apixaban quantified by mass spectrometry. The typical patient was on average 77.2  years old, 85.5 kg, and had a serum creatinine of 103.1 µmol/L. Concomitant amiodarone, an antiarrhythmic agent and moderate CYP3A/ABCB1 inhibitor, the impaired-function variantABCG2 c.421C  >  A, and sex predicted higher apixaban concentrations when controlling for age, weig...
Source: Journal of Thrombosis and Thrombolysis - January 18, 2020 Category: Hematology Source Type: research

D-dimer level in COVID-19 infection: a systematic review.
Authors: Rostami M, Mansouritorghabeh H Abstract INTRODUCTION: COVID-19 disease has spread worldwide from December 2019 to the present day; the early stage of this disease can be associated with high D-dimer, prolonged PT, and elevated levels of fibrinogen, indicating activation of coagulation pathways and thrombosis. In this article, we analyze the levels of D-dimer in patients with COVID-19. AREA COVERED: In the current study, three databases, PubMed, Scopus, Web of Science, searched using related keywords and information extracted from articles such as location, sample size, gender, age, coagulation test val...
Source: Expert Review of Hematology - October 1, 2020 Category: Hematology Tags: Expert Rev Hematol Source Type: research

Severe, Fatal Methotrexate-related Neurotoxicity in 2 Adolescent Patients With ALL
Neurotoxicity is a well-documented adverse effect of methotrexate in the treatment of pediatric cancers. The spectrum of symptoms is broad, can include stroke-like episodes and seizures, and classically resolves within days. The majority of patients tolerate subsequent doses without recurrence of symptoms. The population of patients who experience persistent and irreversible neurologic symptoms is poorly described, with the existing literature suggestive of a relationship with radiation therapy. The authors present a case series of 2 patients with pre-B-cell acute lymphoblastic leukemia who developed severe and ultimately ...
Source: Journal of Pediatric Hematology Oncology - October 23, 2020 Category: Hematology Tags: Online Articles: Clinical and Laboratory Observations Source Type: research

Recovery from acute kidney injury in patients with pulmonary embolism: A single-center study
Pulmonary embolism (PE) ranks as the third most common cardiovascular death after coronary artery disease and stroke [1] and, the second leading cause of death after cancer among cancer patients [2]. Acute Kidney Injury (AKI), defined as an abrupt decrease in kidney function, is associated with adverse short-term and long-term outcomes even in the case of mild and reversible AKI [3]. One-third of patients with PE develop AKI and are at increased risk for bleeding and mortality compared with patients without AKI [4].
Source: Thrombosis Research - January 14, 2021 Category: Hematology Authors: Martin Murgier, L éa Fouillet, Edouard Ollier, Adel Merah, Nathalie Moulin, Sandrine Accassat, Cécile Duvillard, Elodie De Magalhaes, Patrick Mismetti, Manuel Monreal, Laurent Bertoletti Tags: Letter to the Editors-in-Chief Source Type: research

Novel Bleeding Risk Score for Patients with Atrial Fibrillation on Oral Anticoagulants, including Direct Oral Anticoagulants.
CONCLUSION: In this prospective cohort study of AF patients and predominantly DOAC users, we successfully derived a bleeding risk prediction model with good calibration and discrimination. PMID: 33501722 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - January 27, 2021 Category: Hematology Authors: Adam L, Feller M, Syrogiannouli L, Del-Giovane C, Donzé J, Baumgartner C, Segna D, Floriani C, Roten L, Fischer U, Aeschbacher S, Moschovitis G, Schläpfer J, Shah D, Amman P, Kobza R, Schwenkglenks M, Kühne M, Bonati L, Beer J, Osswald S, Conen D, Auje Tags: J Thromb Haemost Source Type: research

Mitochondria-DNA copy-number and incident venous thromboembolism among middle-aged women: a population-based cohort study
AbstractVenous thromboembolism (VTE) is the third most common cardiovascular disease. Low amount of mitochondrial DNA copy number (mtDNA-CN) has been associated with arterial cardiovascular disease (CVD) and reflects mitochondrial dysfunctions. However, whether mtDNA-CN is associated with VTE has not been determined. To examine the association between mtDNA-CN and incident VTE among middle-aged women. 6917 women aged 50 –64 years, followed for 20 years in the Women’s Health In the Lund Area (WHILA) study. DNA samples for mtDNA quantification were available from 2521 women. Quantification of mtDNA-CN was performed usi...
Source: Journal of Thrombosis and Thrombolysis - April 15, 2021 Category: Hematology Source Type: research

Patterns of thromboembolism in patients with advanced pancreatic cancer undergoing 1st-line chemotherapy with FOLFIRINOX or Gemcitabine/nab-paclitaxel
CONCLUSION: Patients with aPC undergoing palliative 1st-line chemotherapy with FOLFIRINOX or GN face a high risk for VTE/ATE and its diagnosis is linked to worse clinical outcomes. VTE-risk prediction models have limited ability to sub-stratify thrombotic events in this high-risk scenario.PMID:34255340 | DOI:10.1055/a-1548-4847
Source: Thrombosis and Haemostasis - July 13, 2021 Category: Hematology Authors: Jakob M Riedl Esther Schwarzenbacher Florian Moik Lena Horvath Antonia Gantschnigg Felix Renneberg Florian Posch Dominik A Barth Michael Stotz Martin Pichler Stefan Hatzl Simon Fandler-H öfler Paul Gressenberger Thomas Gary Philipp Jost Richard Greil Cih Source Type: research

Safety of apixaban for venous thromboembolic primary prophylaxis in patients with newly diagnosed malignant glioma
In this study, we treated ten patients with newly diagnosed MG with apixaban, 2.5  mg twice daily beginning 2–21 days after craniotomy and continuing for up to 6 months. Unacceptable toxicity was defined by ≥ grade 2 CNS or non-CNS hemorrhage, a thromboembolic event (i.e. stroke) or cardiovascular event requiring anticoagulation or anti-platelet therapy. There were no unacc eptable toxicities to report and no treatment-related adverse events. None of the patients on the study were diagnosed with a VTE while receiving apixaban. We conclude that apixaban can be given safely to patients with primary MG shortly after cra...
Source: Journal of Thrombosis and Thrombolysis - August 4, 2021 Category: Hematology Source Type: research

Arterial Thrombosis in Cancer Patients: An Update
Semin Thromb Hemost DOI: 10.1055/s-0041-1733927Cancer is associated with an increased incidence of both venous thromboembolism (VTE) and arterial thrombosis (cardiovascular events and ischemic stroke). Cancer-associated arterial thrombotic events are less well studied than VTE, but increasingly recognized, particularly in specific malignancies and in association with specific anticancer therapies. The pathogenesis of arterial thrombotic events in cancer is complex and involves generation of tumor-associated procoagulant factors and a variety of alterations in platelet function as well as in the coagulation and fibrinolytic...
Source: Seminars in Thrombosis and Hemostasis - August 31, 2021 Category: Hematology Authors: Franchini, Massimo Tufano, Antonella Casoria, Aniello Coppola, Antonio Tags: Review Article Source Type: research

Previously Undiagnosed Cancer in Patients with Arterial Thrombotic Events - A Population-based Cohort Study
CONCLUSION: There is an increased risk of previously undiagnosed cancer at 12 months after ATE, especially in patients without documented vascular risk factors or pre-existent cardiovascular disease.PMID:34818468 | DOI:10.1111/jth.15600
Source: Thrombosis and Haemostasis - November 24, 2021 Category: Hematology Authors: Avi Leader Noa Dagan Noam Barda Idan Goldberg Pia Raanani Galia Spectre Ran Balicer Anat Gafter-Gvili Source Type: research

PO-11: Risk of major bleeding in cancer patients with ischemic stroke treated with thrombolysis
Source: Thrombosis Research - May 1, 2022 Category: Hematology Authors: N. Skajaa, K. Adelborg, F.S. Troelsen, C.H. Fuglsang, E. Horv áth-Puhó, H.T. Sørensen Tags: Posters Source Type: research

Pages: 1  2  3  4  5  6  7